Tag: EPS

Posted on

Q4 2022 EPS Estimates for Citigroup Inc. Raised by Jefferies Financial Group (NYSE:C)

Q4 2022 EPS Estimates for Citigroup Inc. Raised by Jefferies Financial Group (NYSE:C)

Citigroup Inc. (NYSE:C – Get Rating) – Stock analysts at Jefferies Economical Group elevated their Q4 2022 EPS estimates for Citigroup in a study observe issued to investors on Monday, January 9th. Jefferies Fiscal Group analyst K. Usdin now anticipates that the company will article earnings of $1.15 per share for the quarter, up from their prior estimate of $1.07. The consensus estimate for Citigroup’s existing comprehensive-yr earnings is $7.05 per share. Jefferies Money Group also issued estimates for Citigroup’s Q2 2023 earnings at $.79 EPS.

Citigroup (NYSE:C – Get Ranking) last introduced its earnings success on Friday, Oct 14th. The firm reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $.17. The small business had revenue of $18.51 billion for the quarter, in comparison to analyst estimates of $18.28 billion. Citigroup had a web margin of 17.31{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and a return on equity of 9.14{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. Citigroup’s revenue was up 5.9{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} as opposed to the exact same quarter last year. During the exact quarter in the prior year, the company posted $2.49 earnings per share.

A number of other equities investigation analysts have also issued experiences on C. Oppenheimer decreased their selling price focus on on shares of Citigroup from $90.00 to $87.00 and set an “outperform” ranking on the inventory in a report on Wednesday, December 28th. StockNews.com assumed coverage on shares of Citigroup in a report on Wednesday, Oct 12th. They issued a “maintain” score on the stock. Piper Sandler assumed protection on shares of Citigroup in a report on Thursday, December 8th. They issued a “neutral” score and a $48.00 value goal on the inventory. Deutsche Bank Aktiengesellschaft reduced their price tag focus on on shares of Citigroup from $52.00 to $46.00 in a report on Friday. Eventually, Credit rating Suisse Team set a $54.00 selling price concentrate on on shares of Citigroup in a report on Monday, Oct 10th. One particular research analyst has rated the inventory with a market rating, eleven have offered a keep rating and six have issued a buy rating to the company’s stock. In accordance to MarketBeat.com, Citigroup presently has an regular ranking of “Maintain” and a consensus goal price of $57.32.

Citigroup Trading Up .5 {21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}

Shares of Citigroup stock opened at $47.54 on Tuesday. The firm has a market place capitalization of $92.08 billion, a PE ratio of 6.51, a rate-to-earnings-growth ratio of 1.51 and a beta of 1.56. The organization has a credit card debt-to-equity ratio of 1.40, a recent ratio of .93 and a quick ratio of .93. The firm’s fifty working day shifting average price is $46.36 and its two-hundred working day relocating average selling price is $47.38. Citigroup has a 52-7 days low of $40.01 and a 52-week large of $69.11.

Citigroup Dividend Announcement

The small business also lately declared a quarterly dividend, which was compensated on Wednesday, November 23rd. Investors of file on Monday, November 7th ended up supplied a dividend of $.51 for every share. The ex-dividend date was Friday, November 4th. This represents a $2.04 annualized dividend and a generate of 4.29{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. Citigroup’s dividend payout ratio (DPR) is 27.95{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}.

Institutional Inflows and Outflows

Various institutional investors and hedge funds have just lately additional to or minimized their stakes in the inventory. McClarren Fiscal Advisors Inc. bought a new stake in Citigroup during the 3rd quarter worth about $25,000. Corsicana & Co. elevated its holdings in Citigroup by 314.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} for the duration of the 2nd quarter. Corsicana & Co. now owns 659 shares of the firm’s stock truly worth $30,000 soon after getting an extra 500 shares throughout the previous quarter. Householder Team Estate & Retirement Professional LLC purchased a new stake in Citigroup throughout the 3rd quarter truly worth about $28,000. Citizens Nationwide Financial institution Have confidence in Section lifted its holdings in Citigroup by 169.{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} all through the 2nd quarter. Citizens National Financial institution Have faith in Section now owns 780 shares of the firm’s inventory worth $36,000 right after acquiring an further 490 shares all through the very last quarter. Last but not least, Activest Prosperity Management lifted its holdings in Citigroup by 79.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} all through the 2nd quarter. Activest Prosperity Management now owns 792 shares of the firm’s inventory worthy of $36,000 following buying an added 350 shares in the course of the previous quarter. Institutional investors and hedge resources own 70.90{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the firm’s stock.

Citigroup Firm Profile

(Get Score)

Citigroup Inc, a diversified economical expert services keeping corporation, offers different economical products and solutions and companies to individuals, firms, governments, and establishments in North America, Latin America, Asia, Europe, the Center East, and Africa. The corporation operates in two segments, Worldwide Consumer Banking (GCB) and Institutional Shoppers Team (ICG).

Recommended Stories

Earnings History and Estimates for Citigroup (NYSE:C)

This instant news warn was produced by narrative science technological know-how and economical data from MarketBeat in buy to present visitors with the fastest and most accurate reporting. This tale was reviewed by MarketBeat’s editorial workforce prior to publication. Please send any inquiries or feedback about this tale to make contact with@marketbeat.com.

In advance of you contemplate Citigroup, you are going to want to listen to this.

MarketBeat retains observe of Wall Street’s major-rated and most effective carrying out research analysts and the shares they advise to their purchasers on a daily foundation. MarketBeat has determined the five shares that major analysts are quietly whispering to their clientele to purchase now prior to the broader current market catches on… and Citigroup was not on the list.

Though Citigroup currently has a “Hold” score between analysts, leading-rated analysts feel these five stocks are improved purchases.

View The 5 Stocks In this article

Beginners Guide To Retirement Stocks Cover
Posted on

Zacks: Analysts Expect MEDNAX, Inc. (NYSE:MD) to Announce $0.26 EPS

Zacks: Analysts Expect MEDNAX, Inc. (NYSE:MD) to Announce $0.26 EPS

Equities analysts predict that MEDNAX, Inc. (NYSE:MD – Get Rating) will announce earnings of $0.26 per share for the current quarter, Zacks reports. Six analysts have issued estimates for MEDNAX’s earnings. The highest EPS estimate is $0.28 and the lowest is $0.25. MEDNAX posted earnings of $0.24 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that MEDNAX will report full-year earnings of $1.84 per share for the current financial year, with EPS estimates ranging from $1.65 to $1.96. For the next year, analysts anticipate that the business will post earnings of $2.00 per share, with EPS estimates ranging from $1.75 to $2.12. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow MEDNAX.

MEDNAX (NYSE:MD – Get Rating) last announced its quarterly earnings results on Thursday, February 17th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.09. MEDNAX had a return on equity of 15.26{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and a net margin of 6.85{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The business had revenue of $498.53 million for the quarter, compared to analysts’ expectations of $482.50 million. During the same period in the prior year, the firm earned $0.22 EPS. The business’s quarterly revenue was up 19.7{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} on a year-over-year basis.

(Ad)

“Options Basics” is the new traders complete toolbelt, full of plain English instructions, real life  examples, and simple, reliable tactics to get you started!

Several research analysts have recently commented on the company. Zacks Investment Research raised MEDNAX from a “hold” rating to a “strong-buy” rating and set a $27.00 target price on the stock in a report on Tuesday, March 1st. TheStreet raised shares of MEDNAX from a “c” rating to a “b-” rating in a report on Monday, February 28th. Credit Suisse Group reduced their price objective on shares of MEDNAX from $32.00 to $31.00 and set an “outperform” rating for the company in a research note on Wednesday, February 23rd. Finally, StockNews.com raised shares of MEDNAX from a “hold” rating to a “buy” rating in a report on Wednesday, February 23rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $29.63.

In other news, Director Roger Md Medel sold 87,361 shares of the firm’s stock in a transaction dated Tuesday, January 4th. The shares were sold at an average price of $27.43, for a total transaction of $2,396,312.23. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 239,122 shares of company stock valued at $6,478,687. 2.80{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. O Shaughnessy Asset Management LLC lifted its stake in MEDNAX by 5,380.0{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the third quarter. O Shaughnessy Asset Management LLC now owns 1,096 shares of the company’s stock worth $31,000 after acquiring an additional 1,076 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of MEDNAX during the fourth quarter valued at about $57,000. Meeder Asset Management Inc. increased its holdings in shares of MEDNAX by 1,246.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} during the third quarter. Meeder Asset Management Inc. now owns 2,127 shares of the company’s stock valued at $60,000 after acquiring an additional 1,969 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in shares of MEDNAX by 120.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} during the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 3,107 shares of the company’s stock valued at $85,000 after acquiring an additional 1,696 shares in the last quarter. Finally, Captrust Financial Advisors increased its holdings in shares of MEDNAX by 159.6{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} during the third quarter. Captrust Financial Advisors now owns 5,579 shares of the company’s stock valued at $159,000 after acquiring an additional 3,430 shares in the last quarter. Institutional investors own 96.99{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the company’s stock.

NYSE MD traded up $1.28 during trading on Friday, hitting $24.34. 766,267 shares of the company traded hands, compared to its average volume of 513,784. MEDNAX has a 12 month low of $22.31 and a 12 month high of $35.67. The business has a fifty day simple moving average of $24.02 and a 200 day simple moving average of $26.13. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $2.12 billion, a P/E ratio of 15.91, a PEG ratio of 1.52 and a beta of 2.07.

MEDNAX Company Profile (Get Rating)

MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Further Reading

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in MEDNAX right now?

Before you consider MEDNAX, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and MEDNAX wasn’t on the list.

While MEDNAX currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here